Posaconazole for the Treatment of Refractory Keratomycosis A Systematic Review
DOI:
https://doi.org/10.12928/admj.v6i1.12876Keywords:
keratomycosis, fungal keratitis, refractory, posaconazole, antifungalAbstract
Fungal infections such as keratomycosis are one of the most difficult conditions to treat. Approximately half of patients with keratomycosis do not respond to antifungal treatments and carries a higher risk of developing endophthalmitis. If this problem is not treated promptly and effectively, it can lead to vision loss. The use of Posaconazole, a newer triazole, for keratomycosis has attracted new interest due to its broad spectrum and good ocular penetration. Therefore, we conducted a systematic review to assess and conclude the efficacy of posaconazole for refractory keratomycosis. We conducted a systematic review according to PRISMA guidelines. A comprehensive search in PubMed, Scopus, ScienceDirect and Google scholar was conducted from inception to January 2025. Duplicate publications, review articles and incomplete articles were excluded and the quality of the articles were assessed using a standardized tool. The database searches identified a total of 2668 articles. A thorough review of the abstracts and titles led to the exclusion of 1209 items. Finally, we identified 6 articles through full-text reading and analysis, which included 11 patients. All cases reported were successfully treated with posaconazole. In conclusion, posaconazole possibly effective, especially for refractory cases.
References
Mycotic Keratitis—A Global Threat from the Filamentous Fungi [Internet]. Available from: https://www.researchgate.net/publication/350618276_Mycotic_Keratitis-A_Global_Threat_from_the_Filamentous_Fungi
Taechajongjintana M, Kasetsuwan N, Reinprayoon U, Sawanwattanakul S, Pisuchpen P. Effectiveness of voriconazole and corneal cross-linking on Phialophora verrucosa keratitis: a case report. J Med Case Reports [Internet]. 2018 Aug 19 [cited 2025 Jan 10];12:225. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098831/
Lund OE, Miño de Kaspar H, Klauss V. [Strategy for examination and therapy of mycotic keratitis]. Klin Monatsbl Augenheilkd. 1993 Mar;202(3):188–94.
Saha S, Banerjee D, Khetan A, Sengupta J. Epidemiological profile of fungal keratitis in urban population of West Bengal, India. Oman J Ophthalmol [Internet]. 2009 [cited 2025 Jan 10];2(3):114–8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2903915/
Ogawa A, Matsumoto Y, Yaguchi T, Shimmura S, Tsubota K. Successful treatment of Beauveria bassiana fungal keratitis with topical voriconazole. J Infect Chemother Off J Jpn Soc Chemother. 2016 Apr;22(4):257–60.
Anutarapongpan O, Thanathanee O, Suwan-Apichon O. Penicillium keratitis in a HIV-infected patient. BMJ Case Rep. 2016 Aug 17;2016:bcr2016216139.
Xie L, Zhai H, Zhao J, Sun S, Shi W, Dong X. Antifungal susceptibility for common pathogens of fungal keratitis in Shandong Province, China. Am J Ophthalmol. 2008 Aug;146(2):260–5.
Dursun D, Fernandez V, Miller D, Alfonso EC. Advanced Fusarium Keratitis Progressing to Endophthalmitis. Cornea [Internet]. 2003 May [cited 2025 Jan 10];22(4):300. Available from: https://journals.lww.com/corneajrnl/abstract/2003/05000/advanced_fusarium_keratitis_progressing_to.4.aspx
Ishida N, Brown AC, Rao GN, Aquavella JV, del Cerro M. Recurrent Fusarium keratomycosis: a light and electron microscopic study. Ann Ophthalmol. 1984 Apr 1;16(4):354–6, 358–60, 362–6.
Liu X, Sui J, Li C, Wang Q, Peng X, Meng F, et al. The preparation and therapeutic effects of β-glucan-specific nanobodies and nanobody-natamycin conjugates in fungal keratitis. Acta Biomater [Internet]. 2023 Oct 1 [cited 2025 Jan 10];169:398–409. Available from: https://www.sciencedirect.com/science/article/pii/S1742706123004816
Qiu S, Zhao GQ, Lin J, Wang X, Hu LT, Du ZD, et al. Natamycin in the treatment of fungal keratitis: a systematic review and Meta-analysis. Int J Ophthalmol [Internet]. 2015 Jun 18 [cited 2025 Jan 10];8(3):597–602. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4458670/
Arora R, Gupta D, Goyal J, Kaur R. Voriconazole versus natamycin as primary treatment in fungal corneal ulcers. Clin Experiment Ophthalmol. 2011 Jul;39(5):434–40.
Tu EY, McCartney DL, Beatty RF, Springer KL, Levy J, Edward D. Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592). Am J Ophthalmol. 2007 Feb;143(2):222–7.
Tu EY, Park AJ. Recalcitrant Beauveria bassiana keratitis: confocal microscopy findings and treatment with posaconazole (Noxafil). Cornea. 2007 Sep;26(8):1008–10.
Al-Hatmi AMS, Meis JF, de Hoog GS. Fusarium: Molecular Diversity and Intrinsic Drug Resistance. PLoS Pathog [Internet]. 2016 Apr 7 [cited 2025 Jan 10];12(4):e1005464. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824402/
Rajaraman R, Bhat P, Vaidee V, Maskibail S, Raghavan A, Sivasubramaniam S, et al. Topical 5% Natamycin With Oral Ketoconazole in Filamentous Fungal Keratitis: A Randomized Controlled Trial. Asia-Pac J Ophthalmol [Internet]. 2015 May 1 [cited 2025 Jan 10];4(3):146–50. Available from: https://www.sciencedirect.com/science/article/pii/S2162098923005741
Prajna NV, Mascarenhas J, Krishnan T, Ravindranath Reddy P, Prajna L, Srinivasan M, et al. Comparison of Natamycin and Voriconazole for the Treatment of Fungal Keratitis. Arch Ophthalmol [Internet]. 2010 Jun [cited 2025 Jan 10];128(6):672–8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3774126/
ESCRS:Treating Fungal Keratitis [Internet]. [cited 2025 Jan 10]. Available from: https://www.escrs.org/
Raj N, Vanathi M, Ahmed NH, Gupta N, Lomi N, Tandon R. Recent Perspectives in the Management of Fungal Keratitis. J Fungi [Internet]. 2021 Nov [cited 2025 Jan 10];7(11):907. Available from: https://www.mdpi.com/2309-608X/7/11/907
Herbrecht R. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int J Clin Pract. 2004 Jun;58(6):612–24.
Sponsel WE, Graybill JR, Nevarez HL, Dang D. Ocular and systemic posaconazole(SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. Br J Ophthalmol. 2002 Jul;86(7):829–30.
Vanathi M, Naik R, Sidhu N, Ahmed NH, Gupta N, Tandon R. Evaluation of antifungal susceptibility and clinical characteristics in fungal keratitis in a tertiary care center in North India. Indian J Ophthalmol. 2022 Dec;70(12):4270–83.
Izadi A, Dos Santos CO, Mohamadi A, Tehupeiory-Kooreman MC, Soleimani M, Aala F, et al. Assessing the Efficacy of Chlorhexidine in Combating Most Important Causative Agents of Fungal Keratitis: An in Vitro Comparative Study With Seven Antifungal Agents. Curr Eye Res. 2024 Oct 28;1–6.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71.
JBI Manual for Evidence Synthesis - JBI Global Wiki [Internet]. [cited 2025 Jan 16]. Available from: https://jbi-global-wiki.refined.site/space/MANUAL/4687363/Chapter+10%3A+Umbrella+reviews
Kim CK, Karslioglu MZ, Zhao SH, Lee OL. Infectious Keratitis in Patients Over 65: A Review on Treatment and Preserving Eyesight. Clin Interv Aging [Internet]. 2024 Jul 31 [cited 2025 Jan 15];19:1393–405. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11298191/
Akbari M, Sedighi M, Moghadam RS, Kazemnejad E. The epidemiological aspects of fungal keratitis in a population sample from Northern Iran: A cross-sectional study. J Fam Med Prim Care [Internet]. 2022 Jun [cited 2025 Feb 17];11(6):3185–9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9480716/
Mohd-Tahir F, Norhayati A, Siti-Raihan I, Ibrahim M. A 5-year retrospective review of fungal keratitis at hospital universiti sains malaysia. Interdiscip Perspect Infect Dis. 2012;2012:851563.
Ting DSJ, Ho CS, Deshmukh R, Said DG, Dua HS. Infectious keratitis: an update on epidemiology, causative microorganisms, risk factors, and antimicrobial resistance. Eye [Internet]. 2021 Apr [cited 2025 Feb 17];35(4):1084–101. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102486/
Cai Y, Song S, Chen Y, Xu X, Zou W. Oral voriconazole monotherapy for fungal keratitis: efficacy, safety, and factors associated with outcomes. Front Med. 2023;10:1174264.
Kim JY, Yoon KC, Park YG, Cho NC, You IC. Age-related Clinical Analysis of Infectious Keratitis in Two Tertiary Centers. J Korean Ophthalmol Soc [Internet]. 2010 Aug 31 [cited 2025 Jan 15];51(7):927–34. Available from: https://synapse.koreamed.org/articles/1008855
Kim CK, Mekhail JT, Morcos DM, Yang CD, Kedhar SR, Kim C, et al. Three cases of recalcitrant Paecilomyces keratitis in Southern California within a short period. J Ophthalmic Inflamm Infect. 2024 Jan 4;14(1):1.
Barton K, Davis TK, Marshall B, Elward A, White NH. Posaconazole-induced hypertension and hypokalemia due to inhibition of the 11β-hydroxylase enzyme. Clin Kidney J. 2018 Oct;11(5):691–3.
Somerville TF, Shankar J, Aldwinckle S, Sueke H, Neal T, Horsburgh MJ, et al. Recurrent microbial keratitis and endogenous site Staphylococcus aureus colonisation. Sci Rep [Internet]. 2020 Oct 29 [cited 2025 Feb 17];10:18559. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596706/
Tu EY, McCartney DL, Beatty RF, Springer KL, Levy J, Edward D. Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592). Am J Ophthalmol. 2007 Feb;143(2):222–7.
Szaliński M, Zgryźniak A, Rubisz I, Gajdzis M, Kaczmarek R, Przeździecka-Dołyk J. Fusarium Keratitis—Review of Current Treatment Possibilities. J Clin Med [Internet]. 2021 Nov 23 [cited 2025 Jan 15];10(23):5468. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658515/
Castano G, Elnahry AG, Mada PK. Fungal Keratitis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Feb 17]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK493192/
Munayyer HK, Mann PA, Chau AS, Yarosh-Tomaine T, Greene JR, Hare RS, et al. Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds. Antimicrob Agents Chemother. 2004 Oct;48(10):3690–6.
Page AV, Liles WC. Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections. Can J Infect Dis Med Microbiol [Internet]. 2008 Jul [cited 2025 Feb 17];19(4):297–305. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2604777/
Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother. 2003 Sep;47(9):2788–95.
Zhang Q, Zhang J, Gong M, Pan R, Liu Y, Tao L, et al. Transcriptome Analysis of the Gene Expression Profiles Associated with Fungal Keratitis in Mice Based on RNA-Seq. Invest Ophthalmol Vis Sci [Internet]. 2020 Jun 15 [cited 2025 Feb 17];61(6):32. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415296/
Rachwalski EJ, Wieczorkiewicz JT, Scheetz MH. Posaconazole: an oral triazole with an extended spectrum of activity. Ann Pharmacother. 2008 Oct;42(10):1429–38.
Sponsel W, Chen N, Dang D, Paris G, Graybill J, Najvar LK, et al. Topical Voriconazole as a Novel Treatment for Fungal Keratitis. Antimicrob Agents Chemother [Internet]. 2006 Jan [cited 2025 Jan 14];50(1):262–8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1346788/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Adelia Rizka Amila, Jamaluddin Ahmad Ali Mas'ud, Norita Wahyuniawati Asfiana
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
License and Copyright Agreement
In submitting the manuscript to the journal, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal. Please also carefully read Ahmad Dahlan Medical Journal posting Your Article Policy.
- That it is not under consideration for publication elsewhere.
- That its publication has been approved by all the author(s) and by the responsible authorities - tacitly or explicitly - of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
Copyright
Authors who publish with Ahmad Dahlan Medical Journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
